April 6, 2024 Use of the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin following a heart attack did not show a significant benefit in reducing overall heart failure hospitalizations or death from any cause, according to a study presented at the American College of Cardiologys Annual Scientific Session. However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack.
Javed Butler, MD
Despite falling short of its primary endpoint, results from the EMPACT-MI trial found that people who took empagliflozin had a significantly lower risk of certain outcomes directly related to heart failure, including first hospitalization for heart failure, total hospitalization for heart failure and a composite of heart failure hospitalization and death from heart failure, without any increased risk of adverse events.
We found that empagliflozin did not reduce mortality after a heart attack but did reduce the risk of heart failure after heart attack, said Javed Butler, MD, president of the Baylor Scott and White Research Institute in Dallas, distinguished professor of medicine at the University of Mississippi in Jackson, Mississippi, and the studys lead author. To have a 25% to 30% reduction in heart failure hospitalizations is pretty clinically meaningful, but if you put it together with all-cause mortality, it was not a positive study for our primary endpoint.
SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. As evidence has mounted pointing to their benefits in reducing heart failure and other forms of heart disease, researchers have sought to determine whether these drugs could help to prevent heart failure even in people without diabetes or chronic kidney disease.
A heart attack can damage the heart muscle in ways that sometimes lead to heart failure, a condition in which the heart becomes too weak or too stiff to effectively pump blood throughout the body. The EMPACT-MI trial was designed to determine whether SGLT-2 inhibitors could safely help to prevent heart failure and reduce mortality in people with a high risk of heart failure following a heart attack.
The study enrolled 6,522 people treated for acute myocardial infarction at 451 centers in 22 countries. Participants had no history of heart failure but had at least one heart failure risk factor in addition to signs of potential heart dysfunction as indicated by a newly lowered left ventricle ejection fraction to below45% and/or signs or symptoms of congestion requiring treatment. About 32% had Type 2 diabetes. On average, participants were 64 years old and approximately 25% were women and 84% were White. Within 14 days of being admitted to the hospital for a heart attack, half of the participants were randomly assigned to receive empagliflozin at a dose of 10 mg daily, while the other half received a placebo. Researchers tracked outcomes for a median of just under 18 months.
The studys primary composite endpoint occurred in 8.2% of those who received empagliflozin and 9.1% of those receiving a placebo, a difference that was not statistically significant. There was also no difference in the rate of death from any cause, which occurred in 5.2% of those receiving empagliflozin and 5.5% of the control group.
All secondary endpoints related specifically to heart failure outcomes were significantly reduced among patients who received empagliflozin. For example, those receiving empagliflozin were 23% less likely to experience a first heart failure hospitalization and 33% less likely to experience any heart failure hospitalizationincluding recurrent hospitalizationscompared with those taking a placebo. The composite rate of total heart failure hospitalizations and death from heart failure was also 31% lower among those receiving empagliflozin.
Among patients who were not taking common heart failure therapies such as diuretics, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor/neprilysin inhibitor (ARNI) at the time of their initial hospital discharge, those taking empagliflozin were significantly less likely to start such therapies within six months compared with those taking a placebo.
In terms of heart failure outcomes, the data is not only strong, but its consistent with what weve found over the past 10 years in yet another population, Butler said. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.
While as a pragmatic trial design to simplify trial procedures and make it easier on both the participants and the sites, the study had limitations that may have influenced the findings, researchers said. For example, because outcomes were not adjudicated by independent reviewers, outpatient heart failure events were not formally captured as part of the primary endpoint. However, researchers said data on outpatient heart failure visits were collected as part of the study protocols for assessing adverse events. An analysis of these events showed outpatient visits for heart failure were substantially lower in participants who received empagliflozin compared with placebo.
Another limitation was the use of all-cause mortality as part of the primary endpoint, which meant that deaths unrelated to heart failure were included in the endpoint even though the study drug was unlikely to influence them. There were also some unusual circumstances that may have influenced rates of both hospitalization and death, including the COVID-19 pandemic and conflicts involving Russia, Ukraine and Israel, all countries that participated in the trial.
Finally, researchers said that the follow-up period may have been too short to fully capture any difference in mortality related to heart failure. Since people who developed heart failure following their heart attack typically did not begin to show heart failure symptoms until a few months later, any reductions in mortality would not be expected to emerge until after that.
We just did not have long enough follow-up to see whether that heart failure prevention would lead to a benefit in mortality, but its a reasonable clinical thing to say that if youre preventing heart failure, its a good thing, Butler said.
The study was funded by Boehringer Ingelheim and Eli Lilly.
This study was simultaneously published online in the New England Journal of Medicine at the time of presentation.
Butler presented the study, Empagliflozin After Acute Myocardial Infarction: Results of the EMPACTMI Trial, on day one of the 3-day ACC.24 conference.
For more information: http://www.acc.org
Find more ACC24 conference coverage here
More here:
SGLT-2 Inhibitors Show Mixed Results After Heart Attack - Diagnostic and Interventional Cardiology
- Applications of Nanotechnology in the Field of Cardiology - Cureus - April 15th, 2024 [April 15th, 2024]
- Tri-City Cardiology's Ambulatory Surgical Center (ASC) Leads the Way in Revolutionizing Heart Failure Management - PR Newswire - April 15th, 2024 [April 15th, 2024]
- Watchdog group calls out risks associated with private equity in cardiology, other specialties - Cardiovascular Business - April 15th, 2024 [April 15th, 2024]
- Heart health: Cardiologist shares impact of advanced wearable technology on patient monitoring - News9 LIVE - April 15th, 2024 [April 15th, 2024]
- Apr 12 2024 This Week in Cardiology - Medscape - April 15th, 2024 [April 15th, 2024]
- TAVR Found Non-Inferior to SAVR for Low-Risk Patients - Diagnostic and Interventional Cardiology - April 15th, 2024 [April 15th, 2024]
- Telemedicine Strategy After MI Scores a Win in TELE-ACS - TCTMD - April 15th, 2024 [April 15th, 2024]
- Global Interventional Cardiology Devices Market Projected to Reach $21.9 Billion by 2030 - GlobeNewswire - April 15th, 2024 [April 15th, 2024]
- Impact of Interatrial Shunt May Vary by Heart Failure Type - Diagnostic and Interventional Cardiology - April 7th, 2024 [April 7th, 2024]
- No Reduction in 90-Day Deaths, Heart Attacks With Human Apo/A1, A Building Block of HDL Cholesterol - Diagnostic and Interventional Cardiology - April 7th, 2024 [April 7th, 2024]
- Association of Black Cardiologists' "We Are The Faces" Campaign Unveils New Videos for Black Maternal Health Week - PR Newswire - April 7th, 2024 [April 7th, 2024]
- UNC Hospitals Performs First Transcatheter Tricuspid Valve Replacement in North Carolina | Newsroom - UNC Health and UNC School of Medicine - April 7th, 2024 [April 7th, 2024]
- Cardiawave is Presenting the 30-day Follow-up Results from its Valvosoft Pivotal Study on the Teatment of Severe ... - Diagnostic and Interventional... - April 7th, 2024 [April 7th, 2024]
- Real-world Evidence at the American College of Cardiology Scientific Session ACC.24 to Demonstrate Positive Impact ... - Diagnostic and Interventional... - April 7th, 2024 [April 7th, 2024]
- American College of Cardiology Sets Full Range of Education Sessions and Meetings ACC Scientific Session, ACC.24 - Diagnostic and Interventional... - April 7th, 2024 [April 7th, 2024]
- ACC.24: Smidt Heart Institute Experts to Share Research Findings, Clinical Knowledge - Diagnostic and Interventional Cardiology - April 7th, 2024 [April 7th, 2024]
- Cardiovascular Research Foundation, CRF, Introduces New York Valves: The Structural Heart Summit - Diagnostic and Interventional Cardiology - April 7th, 2024 [April 7th, 2024]
- Medicare drops AUC requirement for advanced imaging, ASNC celebrates - Cardiovascular Business - April 7th, 2024 [April 7th, 2024]
- Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions - Yale School of Medicine - April 7th, 2024 [April 7th, 2024]
- Getting Too Little Sleep Linked to High Blood Pressure - Diagnostic and Interventional Cardiology - April 7th, 2024 [April 7th, 2024]
- What's Going to Be Hot at ACC 2024 - TCTMD - April 7th, 2024 [April 7th, 2024]
- E-cigarette use linked to increased risk of heart failure, large study finds - News-Medical.Net - April 7th, 2024 [April 7th, 2024]
- Osso VR and ACC to Develop Cardiac Procedure Training with VR - HIT Consultant - April 7th, 2024 [April 7th, 2024]
- Kapil Yadav, M.D., Joins UAMS to Lead Nuclear Cardiology and Vascular Medicine Program - UAMS News - March 19th, 2024 [March 19th, 2024]
- Doctors form new coalition focused on reducing private equity's role in cardiology, other healthcare specialties - Cardiovascular Business - March 19th, 2024 [March 19th, 2024]
- Beth Israel Deaconess Medical Center cardiologist to be honored by American Heart Association - American Heart Association - March 19th, 2024 [March 19th, 2024]
- March 19 Doctors on Call Will Focus on Cardiology - KRSL - March 19th, 2024 [March 19th, 2024]
- Cardiologist shares his long journey from Libya to United States - Cardiovascular Business - March 19th, 2024 [March 19th, 2024]
- Cardiologists share historic research that led to FDA's long-awaited approval of coronary DCB - Cardiovascular Business - March 19th, 2024 [March 19th, 2024]
- Most physicians think private equity is bad for healthcare - Cardiovascular Business - March 19th, 2024 [March 19th, 2024]
- Meth-Related Cardiomyopathy: Where the Biggest Clusters Are - Medpage Today - March 19th, 2024 [March 19th, 2024]
- Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports - Diagnostic and Interventional Cardiology - March 19th, 2024 [March 19th, 2024]
- SS Innovations' SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement - Diagnostic and Interventional Cardiology - March 19th, 2024 [March 19th, 2024]
- Intravascular imaging during PCI in heart disease patients improves survival, reduces adverse outcomes - News-Medical.Net - March 19th, 2024 [March 19th, 2024]
- PA Martine Altieri Brings an Obesity Medicine Clinic to Her Cardiology Patients - AAPA - March 11th, 2024 [March 11th, 2024]
- WEGOVY APPROVED FOR HEART RISK: U-Mich cardiology, obesity medicine experts available for interview - Newswise - March 11th, 2024 [March 11th, 2024]
- AHA Sums Up AI's Potential in Cardiology, but Also the Hurdles Ahead - TCTMD - March 11th, 2024 [March 11th, 2024]
- Houston cardiology-focused tech platform exits to private equity, plans to scale - InnovationMap - March 11th, 2024 [March 11th, 2024]
- The Daylight Saving Time Health Effects You Might Not Be Expecting, According to a Cardiology Specialist (Exclusive) - PEOPLE - March 11th, 2024 [March 11th, 2024]
- How a big CMS update on carotid stenting could impact interventional cardiology - Cardiovascular Business - March 11th, 2024 [March 11th, 2024]
- Global Cardiology Medical Imaging Informatics Market - Cloud-powered Telecardiology to Improve Access to Healthcare - PR Newswire - March 11th, 2024 [March 11th, 2024]
- Valley Health cardiologist talks regional heart health | Nvdaily | nvdaily.com - Northern Virginia Daily - March 11th, 2024 [March 11th, 2024]
- With the correct research, AI in pediatric cardiology has great potential - Contemporary Pediatrics - March 11th, 2024 [March 11th, 2024]
- Top in cardiology: Cannabis use, heat exposure associated with higher stroke risk - Healio - March 11th, 2024 [March 11th, 2024]
- Researcher promotes subsidies to bring cardiac care closer to home in rural areas - Montana Right Now - March 11th, 2024 [March 11th, 2024]
- Cardiologist aims to improve care, reduce costly air transport - The Taos News - March 11th, 2024 [March 11th, 2024]
- Long-term Survivors of Childhood Cancer at Higher Risk of Death Following Heart Issues; Threshold for Treating Risk ... - Diagnostic and... - February 29th, 2024 [February 29th, 2024]
- Even Modest Lp(a) Elevations Bode Poorly for Cardiovascular Health - Medpage Today - February 29th, 2024 [February 29th, 2024]
- Bojangles surprises CMC cardiology team with heart-shaped biscuits for Heart Month - wpde.com - February 29th, 2024 [February 29th, 2024]
- Health Beat: Local cardiologists raise awareness about heart disease prevention - Iredell Free News - February 29th, 2024 [February 29th, 2024]
- Miami Valves 2024 Showcases Innovations in Structural Heart and Cardiovascular Care - InventUM - University of Miami - February 29th, 2024 [February 29th, 2024]
- Cardiology Specialists Keep a Pulse on Adults Born with Heart Defects - Checkup Newsroom - February 29th, 2024 [February 29th, 2024]
- A Living Legend of Health Equity in Stroke and Heart Disease - Penn Medicine - February 29th, 2024 [February 29th, 2024]
- Cardiologist at heart of TAVR controversy loses hospital privileges due to 'disruptive,' 'inexplicable' behavior - Cardiovascular Business - February 29th, 2024 [February 29th, 2024]
- Integration of pharmacist-led pharmacogenomics testing in cardiology clinical practice - Healio - February 29th, 2024 [February 29th, 2024]
- Foiled Theft of Medicines at Punjab Institute of Cardiology Highlights Organized Crime Concerns - BNN Breaking - February 29th, 2024 [February 29th, 2024]
- Feb 23 2024 This Week in Cardiology - Medscape - February 29th, 2024 [February 29th, 2024]
- Hospital doesnt miss a beat when it comes to cardiac care - Martha's Vineyard Times - February 29th, 2024 [February 29th, 2024]
- Cardiologist on the beat for healthy hearts | News, Sports, Jobs - Marietta Times - February 29th, 2024 [February 29th, 2024]
- One of few females in her field, Dr. Sheth focuses on educating women about heart health - Chicago Tribune - February 29th, 2024 [February 29th, 2024]
- URMC Hosts 'Heartbeat of Upson' Celebration | Lifestyle | upsonbeacon.com - upsonbeacon.com - February 29th, 2024 [February 29th, 2024]
- WVU, Valley Health offer pediatric cardiology in Tri-State | Special Sections | loganbanner.com - The Logan Banner - February 29th, 2024 [February 29th, 2024]
- First patient treated using A-Flux Reducer interventional system for angina - Cardiac Rhythm News - February 29th, 2024 [February 29th, 2024]
- Happy Holidays from the Diagnostic and Interventional Cardiology Team - Diagnostic and Interventional Cardiology - December 31st, 2023 [December 31st, 2023]
- 7 New Year's Resolutions for Heart Health From Cardiologists - Livestrong - December 31st, 2023 [December 31st, 2023]
- Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation ... - Diagnostic and Interventional... - December 31st, 2023 [December 31st, 2023]
- Smidt Heart Institute at Cedars-Sinai opens Aortic Surveillance Clinic for patients with enlarged aortas - News-Medical.Net - December 31st, 2023 [December 31st, 2023]
- Creatinine and Cystatin C-based GFR Estimation in HF Mortality - Physician's Weekly - December 31st, 2023 [December 31st, 2023]
- Holidays linked to surge in heart attacks, warns cardiology chief ahead of Christmas - WTOV Steubenville - December 22nd, 2023 [December 22nd, 2023]
- 5 trends in cardiology to watch - Harvard Health - December 22nd, 2023 [December 22nd, 2023]
- Top Policy and Practice News for Cardiologists in 2023 - TCTMD - December 22nd, 2023 [December 22nd, 2023]
- Colchicine Not the Answer for Recurring Arrhythmias After Ablation - Medpage Today - December 22nd, 2023 [December 22nd, 2023]
- Chamber Cardio Launches Innovative Value-Based Cardiology Care Platform with Early Success - PR Newswire - December 22nd, 2023 [December 22nd, 2023]
- Drinking in moderation can help avoid 'holiday heart syndrome' - UT Southwestern - December 22nd, 2023 [December 22nd, 2023]
- Top Cardiology Trials and Studies of 2023: Insights and Breakthroughs - Medriva - December 22nd, 2023 [December 22nd, 2023]
- Overview of Major Cardiology Trials in 2023 - Medriva - December 22nd, 2023 [December 22nd, 2023]
- New drugs, updated treatment strategies: 5 important trends in cardiology from an eventful 2023 - Cardiovascular Business - December 22nd, 2023 [December 22nd, 2023]
- The Top Cardiology Trials of 2023 - Medscape - December 22nd, 2023 [December 22nd, 2023]
- Cardiologists' Holiday Wish: Medicare Pay Cuts Roasting on an Open Fire - TCTMD - December 22nd, 2023 [December 22nd, 2023]
- Dec 15 2023 This Week in Cardiology - Medscape - December 22nd, 2023 [December 22nd, 2023]